PROFITABILITY ACROSS ALL BUSINESS LINES
IBA will report
- High order intake across all business lines
- Proton Therapy saw a continued revival in activity with five systems (nine rooms) sold in
Asia ,Europe and the US, compared with two systems sold in the prior year - Other Accelerators had another excellent year with more than 30 systems sold, up from 17 systems last year
- The Dosimetry business has continued to perform well with order intake in line with the prior year
- Proton Therapy saw a continued revival in activity with five systems (nine rooms) sold in
- Equipment and Services backlog at a new all-time high of
EUR 1.2 billion - Highly active pipeline, particularly in the US and
Asia , with continuing momentum providing significant visibility for 2022 and beyond - All time high net cash position of
EUR 130.3 million (unaudited) at year end, providing the business a solid foundation to progress its strategic objectives
IBA will publish its consolidated results for the full year 2021 on Thursday,
In addition to the press release,
Conference Call Information
This conference call will be held on Thursday,
If you would like to join by phone only, please dial (Phone conference ID 913 259 995#):
Belgium: +32 2 890 97 20
UK: +44 20 3321 5200
NL: +31 20 708 6901
LU: +352 27 87 00 02
US: +1 347-991-7591
FR: +33 1 70 99 53 51
The presentation will be available on IBA’s investor relations website and on:
https://www.iba-worldwide.com/content/iba-full-year-2021-results-press-release-and-web-conference shortly before the call.
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.
Shareholder’s Agenda
Full Year Results
Business Update First Quarter 2022
General Assembly
Half Year 2022 Results
Business Update Third Quarter 2022
***Ends***
About IBA
IBA (
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
CONTACTS
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
+44 (0) 20 3709 5700
IBA@consilium-comms.com
Attachment
- 220201-IBA_2021_Trading_Update-EN
© OMX, source